The Effect of Bevacizumab on Corneal Neovascularization

Corneal Neovascularization Clinical Trial

— BQ-1-08-ARVO  

Official title:

The Effect of Bevacizumab on Corneal Neovascularization

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00797303
• Other study ID #: BQ-1-08-ARVO
• Status: Completed
• Phase: Phase 4
• First received: November 22, 2008
• Last updated: December 1, 2011
• Start date: January 2006
• Est. completion date: November 2008

Study information

• Verified date: November 2011
• Source: Instituto de Olhos de Goiania
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: National Health Surveillance Agency
• Study type: Interventional

Clinical Trial Summary

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Description:

To evaluate the effect of repeated subconjunctival bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) on inflammatory corneal neovascularization.

Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: November 2008
• Est. primary completion date: July 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Corneal Neovascularization

• Stable lesion

Exclusion Criteria:

• Diabetes

• Autoimmune diseases

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Corneal Neovascularization
• Neovascularization, Pathologic

Intervention

Drug:
• Bevacizumab
subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Instituto de Olhos de Goiania

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Effect of Bevacizumab on Corneal Neovascularization	Eight patients with corneal neovascularization were treated with subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months. All patients had persistent corneal neovascularization for at least 6 months unresponsive to other treatments. Patients were monitored by ophthalmic exam and anterior segment photography	Compare the results	Yes